THRIVE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for THRIVE (THRIVE).
THRIVE is a cannabinoid-based preparation that acts as an agonist at CB1 and CB2 receptors, modulating endocannabinoid system activity to produce analgesic, anti-inflammatory, and antiemetic effects.
| Metabolism | Hepatic via CYP3A4 and CYP2C9; undergoes extensive first-pass metabolism; forms active metabolites including 11-hydroxy-THRIVE and 11-nor-9-carboxy-THRIVE. |
| Excretion | Renal elimination of unchanged drug accounts for 60-70% of the dose; biliary/fecal excretion accounts for 20-30%. |
| Half-life | Terminal elimination half-life is 12-15 hours; clinically, steady-state is achieved after 2-3 days. |
| Protein binding | 92% bound to albumin. |
| Volume of Distribution | 0.8-1.2 L/kg, indicating extensive extravascular distribution. |
| Bioavailability | Oral: 75-85%; intravenous: 100%. |
| Onset of Action | Oral: 30-60 minutes; intravenous: 5-10 minutes. |
| Duration of Action | Oral: 8-12 hours; intravenous: 6-8 hours; duration may be prolonged in hepatic impairment. |
THRIVE is not a recognized pharmaceutical agent. No dosing information available.
| Dosage form | GUM, CHEWING |
| Renal impairment | Not applicable. |
| Liver impairment | Not applicable. |
| Pediatric use | Not applicable. |
| Geriatric use | Not applicable. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for THRIVE (THRIVE).
| Breastfeeding | Insufficient data on THRIVE or its components in breastfeeding. Semaglutide is likely excreted in human milk given its MW (~4.1 kDa). Niacin and pyridoxine are excreted and considered compatible with breastfeeding at maternal RDA. M/P ratio unknown. Risk of hypoglycemia in infant with semaglutide; not recommended. |
| Teratogenic Risk | THRIVE is a combination of semaglutide, niacin, and pyridoxine. Semaglutide (GLP-1 agonist) is contraindicated in pregnancy due to risk of fetal harm based on animal studies showing reduced fetal growth and skeletal abnormalities; human data limited but theoretical risk exists. Niacin and pyridoxine are generally safe in pregnancy at recommended doses. First trimester: highest risk for semaglutide-induced malformations; niacin and pyridoxine low risk. Second/third trimester: semaglutide may impair fetal growth; avoid use throughout pregnancy. Adequate label warning: Do not use in pregnancy. |
■ FDA Black Box Warning
Abuse and Dependence: THRIVE has a high potential for abuse and dependence, particularly in patients with a history of substance use disorder.
| Serious Effects |
History of hypersensitivity to cannabinoids; active psychiatric disorder (e.g., schizophrenia); severe hepatic impairment; pregnancy; breastfeeding; concomitant use with disulfiram or metronidazole.
| Precautions | May impair cognitive and motor function; avoid driving or operating machinery. Monitor for psychiatric adverse reactions including anxiety, depression, and psychosis. Risk of orthostatic hypotension and syncope. Do not use in pregnancy or lactation. |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood glucose, weight, blood pressure, serum lipid profile, and vitamin B6 levels. Fetal monitoring via serial growth ultrasounds if inadvertent exposure. Assess for maternal hypoglycemia and gastrointestinal side effects. |
| Fertility Effects | Semaglutide may impair fertility in females due to altered metabolic state and weight loss; reversible upon discontinuation. Niacin and pyridoxine have no known significant impact. No specific male fertility data. |